-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Up to 25% of patients with inflammatory bowel disease (IBD) are diagnosed in childhood or adolescence.
In recent decades, the incidence of IBD in children has been on the rise, and although IBD patients may have similar symptom spectrum, patients with early onset of IBD often exhibit different disease esolyses than older IBD patients or adult IBD patients.
less than 6 years of age at the time of diagnosis is defined as very early onset of IBD (VEOIBD), inflixi monoantigen (IFX) has been shown to be effective in treating children with CD.
that 59-89% of CD patients received clinical remission after IFX-induced treatment.
, however, children under the age of 6 lacked these data.
, this study aims to assess the effectiveness and safety of inflixi monotherapy for CD patients in children.
researchers reviewed pediatric Crohn's disease activity index, Crohn's endoscope index scores, height and weight at baseline, weeks 14 and 54.
compared the clinical remission rate and mucous membrane healing rate and growth rate of patients younger than and older than 25 years of age.
assessed the loss or non-reaction of the child's reaction to inflixi monoantigen and adverse events throughout the treatment period.
the study recruited 65 children.
64% and 40.0% of patients with very early onset of Crohn's disease achieved clinical remission and mucosal healing after induction therapy.
correcting the co-variance, the early onset of the disease is independent of primary non-reactiveness (p s 0.360) or mucous membrane healing (p s 0.361).
onset of the disease is associated with the termination of inflixi monoantigen due to adverse events (risk ratio of 7.15, 95% CI 1.73-29.51, p s 0.006).
this study confirms that Crohn's disease has a similar rate of non-reactive and mucosal healing to those induced to treat people over 6 years of age if the patient begins to attack at a very young age.
in patients with very early Crohn's disease observed more frequent deactivation of inflixi monoactivation due to adverse events.
